CICON24 focuses on the theme of Translating Science into Survival, highlighting notable plenaries presented by prominent figures in the field, along with selected proffered talks derived from the pool of submitted abstracts plus exhibits and networking opportunities.

SUNDAY, SEPTEMBER 8, 2024

8:00 AM
Welcome

• Jill O’Donnell-Tormey, Cancer Research Institute

• Alicia Zhou, Cancer Research Institute

8:15 AM - 9:45 AM
Session 1: Neoadjuvant and Platform Trials
Session Chair: Elizabeth Jaffee

• Mark Yarchoan, Johns Hopkins University School of Medicine
  Neoadjuvant immunotherapy in hepatocellular carcinoma (HCC): Downstaging into resectable disease with enhanced antitumor immunity

• Luis Diaz, Memorial Sloan Kettering Cancer Center
  Immunoablative neoadjuvant therapy

• Elizabeth Jaffee, Johns Hopkins University School of Medicine
  Neoadjuvant immunotherapy turns pancreatic cancer into an immune responsive disease

9:45 AM - 10:15 AM REFRESHMENT BREAK

10:15 AM - 11:45 AM
Session 2: Multiomic Data Analysis: Searching for Mechanistic Insights -
Beyond just atlas-ing, Part I
Session Chair: Dana Pe’er

• Max Krummel, UCSF Helen Diller Family Comprehensive Cancer Center
  Discovering and applying immune archetypes for cancer therapy

• Dana Pe’er, Memorial Sloan Kettering Cancer Center
  From cells to gene programs and tumor progression

• Chuck Drake, Johnson & Johnson
  Profiling the TME in prostate cancer — Neoadjuvant and metastatic IO studies

11:45 AM - 1:45 PM LUNCH AND POSTER SESSION A

1:45 PM - 3:15 PM
Session 2: Multiomic Data Analysis: Searching for Mechanistic Insights -
Beyond just atlas-ing, Part II
Session Chair: Dana Pe’er

• Benjamin Greenbaum, Memorial Sloan Kettering Cancer Center
  Inferring tumor immune interactions

• Elana Fertig, Johns Hopkins University School of Medicine
  Computational modeling of multi-omics for predictive immunotherapy

• Kevin Wang, University of Pennsylvania
  Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8 T cells (proffered)

• Qin Zhu, University of California, San Francisco
  Mapping the T cell state manifold across time and perturbation (proffered)

REFRESHMENT BREAK (3:15 PM - 3:35 PM)

3:35 PM - 6:05 PM
Session 3: Tertiary Lymphoid Aggregates as Regulators of Anti-Cancer Immunity
Session Chair: Wolf Hervé Fridman

• Nir Hacohen, Massachusetts General Hospital
  The spatial organization of immune cells in tumors

• Wolf Hervé Fridman, Cordeliers Research Center, Paris
  Determinants of tumor immunity and response to immunotherapy in TLS containing tumors

• Kevin Ng, The Rockefeller University
  Germinal center responses to tumor antigens (proffered)

• Hye Mi Kim, University of Pittsburgh
  Temporal evaluation of tertiary lymphoid structures reveals changes in activity and composition over time (proffered)

• Tullia Bruno, University of Pittsburgh
  Harnessing B cells within and outside tertiary lymphoid structures for improved therapeutics

• Alessandra Vaccaro, Uppsala University
  Customizing tumor vessels to promote immune hubs and anti-cancer immunity

7:00 PM Welcome Reception

MONDAY, SEPTEMBER 9, 2024

8:00 AM
Keynote Address

• Cathy Wu, Dana-Farber Cancer Institute
  Personalized cancer vaccines: Encouraging results and new opportunities

8:40 AM - 10:40 AM
Session 4: Cancer Interception - Immune Health and Inflammation as Precursors to Cancer
Session Chair: Ellen Puré, University of Pennsylvania

• Amanda Lund, New York University
  Deconvolving the impact of lymphatic transport on tumor immune surveillance

• Matthew Spitzer, University of California, San Francisco
  A systemic inflammatory resistance circuit amplified by effector T cells

• Allie Greenplate, University of Pennsylvania
  Immune health: The next frontier of precision medicine

• Valentin Barthet, Memorial Sloan Kettering Cancer Center
  Targeting senescent cells with precision: A nanoparticle approach to combat fibrosis and enhance cancer immunotherapy

• James Reading, University College London
  Weaponizing preinvasive CD4 T cell networks enables interception of lung squamous carcinogenesis (proffered)

REFRESHMENT BREAK (10:40 AM - 11:10 AM)

11:10 AM - 1:25 PM
Session 5:  The Role of Myeloid Cells in the Anti-tumor Response
Session Chair: Antonio Sica, IRCCS Humanitas Clinical and Research Centre         

• Gregory Beatty, University of Pennsylvania
  Activating anti-tumor immunity through coordinated myeloid activation

• Evanthia Roussos-Torres, University of Southern California
  Dynamic rewiring of myeloid cell interactions to suppress suppression within the metastatic tumor microenvironment

• Jennifer Guerriero, Brigham and Women’s Hospital / Harvard Medical School
  Targeting macrophage lipid metabolism to enhance anti-tumor responses

• Ming Li, Memorial Sloan Kettering Cancer Center
  Reprogramming tumor-associated macrophages to suppress cancer progression

• Matthew Park, Icahn School of Medicine at Mount Sinai
  Hematopoietic aging promotes lung cancer by fueling IL-1⍺-driven emergency myelopoiesis (proffered)

1:25 PM - 3:00 PM LUNCH

3:00 PM - 4:45 PM
Session 6: What’s on the Horizon: New Tools, Technologies, and Approaches in Cancer Immunotherapy, Part I
Session Chair: Dana Pe’er

Short Talks & Panel Discussion

• Dana Pe’er, Memorial Sloan Kettering Cancer Center, Moderator

• Hector Corrada Bravo, Genentech

• Elana Fertig, Johns Hopkins Medicine

• Ben Greenbaum, Memorial Sloan Kettering Cancer Center

• Nir Hacohen, Massachusetts General Hospital

REFRESHMENT BREAK (4:45 PM - 5:15 PM)

5:15 PM - 6:15 PM
Proffered Session: What’s on the Horizon: New Tools, Technologies, and Approaches in Cancer Immunotherapy, Part II
Session Chair: Dana Pe’er

• Filipe Pereira, Leiden University
  A cancer immunotherapy modality based on dendritic cell reprogramming in vivo (proffered)

• Xingwu Zhou, University of Michigan
  Crystalized cyclic dinucleotide manganese nanoparticles potentiate systemic STING activation across multiple species (proffered)

• Chiara Falcomata, Icahn School of Medicine at Mount Sinai
  Identifying mechanisms of tumor immune composition control in pancreatic cancer (proffered)

• Raymond Shim, University of Calgary
  Sympathetic nerves assist in growth of experimental liver metastases independently of β-adrenergic receptors (proffered)

TUESDAY, SEPTEMBER 10, 2024

8:30 AM
William B. Coley Lecture

• Diane J. Mathis, Harvard Medical School
  Thymic mimetic cells: Tolerogenic masqueraders

9:10 AM - 11:55 AM
Session 7: Metabolic Pathways in the Clinic
Session Chair: Guido Kroemer, Gustave Roussy Cancer Center

• Hongbo Chi, St. Jude Children’s Research Hospital
  Functional genomics in mapping the metabolic basis of cancer and tissue immunity

• Marina Baretti, Johns Hopkins University School of Medicine
  Exploiting a critical vulnerability to glutamine antimetabolite therapy in fibrolamellar hepatocellular carcinoma (FLC)

  REFRESHMENT BREAK (10:10 AM - 10:40 AM)

• Shixin Ma, Salk Institute for Biological Studies
  Nutrient-driven histone code determines exhausted CD8+ T cell fates (proffered)

• Ping-Chih Ho, University of Lausanne
  Stressed mitochondria guide T cell exhaustion

• Susan Kaech, Salk Institute for Biological Studies
  Fueling T cell fate decisions in cancer

11:55 AM - 2:00 PM LUNCH AND POSTER SESSION B

2:00 PM - 5:15 PM
Session 8: Diet and Microbiome
Session Chair: Andrew Y. Koh

• Jennifer Wargo, The University of Texas MD Anderson Cancer Center
  Targeting the microbiome to promote health and end cancer 

• Andrew Y. Koh, University of Texas Southwestern
  Gut microbiota and cancer immunotherapy

• Tal Danino, Columbia University
  Engineering bacteria for cancer therapy

  REFRESHMENT BREAK (3:30 PM - 4:00 PM)

• Maria Rescigno, Humanitas University, Milano
  Microbiota in cancer progression and therapy

• Saman Maleki, Western University
  The gut microbiome effect on anti-tumor immunity and response to immunotherapy

• Laura Lucia Cogrossi, IRCCS San Raffaele Scientific Institute, Milano, Italy
  High fiber dietary intervention in plasma cell dyscrasias improves disease biomarkers and delays progression to myeloma (proffered)

WEDNESDAY, SEPTEMBER 11, 2024

8:30 AM - 12:00 PM
Session 9:  Cellular Therapies & Cancer Vaccines: Moving Toward Personalization
Session Chair: Yvonne Chen, University of California, Los Angeles

• Magnus Essand, Uppsala University
  Arming CAR-T cells for potent bystander anti-tumor immune responses in glioblastoma

• Maria Themeli, University of Amsterdam
  Combination of targets, costimulation and logic-gating to enhance and control CAR T cell function

• Gianpietro Dotti, UNC Lineberger Comprehensive Cancer Center
  Innate CAR-natural killer T cells

• Neeha Zaidi, Johns Hopkins University School of Medicine
  Harnessing the immune system against mutant KRAS

  REFRESHMENT BREAK (10:30 AM - 10:45 AM)

• Kasidet Manakongtreecheep, Harvard Medical School
  Sensitive direct detection of cancer-specific antigens via user-defined peptide spectral libraries (proffered)

• Yu-Chan Chih, German Cancer Research Center (DKFZ)
  Targeting glioblastoma stem cells with a vaccine-induced HLA-A*02-restricted TCR specific to the cancer-associated antigen PTPRZ1 (proffered)

• Vinod Balachandran, Memorial Sloan Kettering Cancer Center
  RNA vaccines for pancreatic cancer

Conference Co-Chairpersons
Elizabeth M. Jaffee, Johns Hopkins, Baltimore, MD
Guido Kroemer, Gustave Roussy Cancer Center, Villejuif, France
Dana Pe’er, Memorial Sloan Kettering Cancer Center, New York, NY
Özlem Türeci, BioNTech, Mainz, Germany

Committee Members
James P. Allison, University of Texas M.D. Anderson Cancer Center, Houston, TX
Tullia Bruno, University of Pittsburgh, Pittsburgh, PA
Giulia Casorati, IRCCS Ospedale San Raffaele, Milan, Italy
Yvonne Chen, UCLA, Los Angeles, CA
Lisa Derosa, Gustave Roussy Cancer Center, Villejuif, France
Mustafa Diken, TRON-Translational Oncology, Mainz, Germany
Wolf Hervé Fridman, Cordeliers Research Center, Paris, France
Ming Li, Memorial Sloan Kettering Cancer, New York, NY
Johanna Olweus, Oslo University Hospital, Oslo, Norway
Ellen Puré, University of Pennsylvania, Philadelphia, PA
Antonio Sica, IRCCS Humanitas Clinical and Research Centre, Rozzano, Milan, Italy
Gregory Sonnenberg, Weill Cornell Cancer Center, New York, NY